Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-114 and Amivantamab in EGFR Exon 20 Insertion Mutant NSCLC
NCT06816992Phase 1Recruiting
- Sponsor
- ORIC Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of enozertinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 12 months, Objective Response Rate at 12 months and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
enozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06816992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816992.